Ocular Therapeutix (OCUL) Insider Trades, Congress & Funds

Smart money at a glance

Filings to Oct 30, 2026

Net selling: insiders sold $568K and bought $0 on the open market in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.

Company insidersSEC Form 4, last 90 days: -$568K netNet selling
CongressSTOCK Act, last 180 days: NoneNo trades disclosed
Big fundsSEC 13F, quarter ended Mar 31, 2026: 1 added, 2 cutMore cutting
Federal contractsUSAspending.gov, last 12 months: No awardsNone on record

Analysts

What do analysts expect?

Analyst target and ratings are on paid plans

See the 12-month consensus target and the buy/hold/sell rating split.

Unlock the full results

Questions about OCUL filings

Are insiders buying or selling Ocular Therapeutix Inc (OCUL) stock?

Net selling: insiders sold $568K and bought $0 of OCUL stock on the open market in the 90 days to Oct 30, 2026, according to SEC Form 4 filings. $556K of the sales were made under pre-set Rule 10b5-1 trading plans. The largest was Dugel, Pravin (See Remarks), who sold $233K. The latest filing was on Oct 13, 2026.

Which members of Congress have traded OCUL recently?

None. No member of Congress disclosed a OCUL trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.

How current is this OCUL smart-money data?

This summary uses filings available on Oct 30, 2026. Insiders must report trades to the SEC within 2 business days, members of Congress have up to 45 days to disclose a trade, and funds file 13F holdings up to 45 days after each quarter ends, so the latest moves may not be public yet.

13F: filed up to 45 days late.

Smart money on OCUL

Lean short2 sources:
- Insiders
- Funds

Top traders
No tracked positions at the last update
Insiders
Lean short3 sales · $234K
3 of 3 on scheduled plans. Form 4 filings.
Politicians
No recent politician filings found
Funds
Lean short1 added · 2 trimmed
Quarter-end 13F holdings changes, not live trades. A trim is not a short.
Fin-fluencers
No recent posts found

Each bar is 100% of that source’s money. The notch marks an even split.

Lean is the direction of the latest moves. Descriptive, not advice.

Questions about OCUL filings

Are insiders buying or selling Ocular Therapeutix Inc (OCUL) stock?

Which members of Congress have traded OCUL recently?

None. No member of Congress disclosed a OCUL trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.

How current is this OCUL smart-money data?

Funds

What funds are doing

3 moves · 6 mo

Buys/Adds$34.5MSells/Trims$63.3M

Buys/Adds (1)

P7
Point72
Steven Cohen · Q1 2026 13F
$34.5M
added
Signals like this: n=13770, 53% finished lower at D15, median -0.4% vs SPY -0.4%

Sells/Trims (2)

MI
Millennium
Israel Englander · Q1 2026 13F
$38.7M
trimmed
Signals like this: n=7469, 53% finished lower at D15, median -0.5% vs SPY -0.4%
CI
Citadel
Ken Griffin · Q1 2026 13F
$24.7M
trimmed

Unlock everything for $29/month

Unlock for $29/month

Reported Aug 3, 2026

Earnings came in 9.4% above what analysts expected.

Documents

Quarterly report10-Q Annual report10-K Every filing

Last report

Aug 3, 2026

Period ending

Jun 30, 2026

Earnings per share

-$0.35+9.44% beat

-$0.39 expected

Revenue

$13.5M

SEC filing

EPS: Yahoo Finance

Next report

Estimated report: Nov 3, 2026, in 4 days

Previous reports

Quarter / reported	Earnings per share	Beat or miss	Revenue / income	Revenue vs last year
Jun 30, 2026Reported Aug 3, 2026	-$0.35est. -$0.39	+9.44%beat	$13.5MSEC filing	+0.1%from $13.5M
Mar 31, 2026Reported May 5, 2026	-$0.40est. -$0.32	-27.59%miss	$10.8MSEC filing	+0.8%from $10.7M
Dec 31, 2025Reported Feb 5, 2026	-$0.29est. -$0.34	+13.86%beat	$13.3MYahoo Finance	No year-ago quarter
Sep 30, 2025Reported Nov 4, 2025	-$0.38est. -$0.35	-9.61%miss	$14.5MSEC filing	-5.7%from $15.4M
Jun 30, 2025Reported Aug 5, 2025	-$0.39est. -$0.35	-11.43%miss	$13.5MSEC filing	-18.1%from $16.4M
Mar 31, 2025Reported May 5, 2025	-$0.37est. -$0.28	-32.14%miss	$10.7MSEC filing	-27.6%from $14.8M
Dec 31, 2024Reported Mar 3, 2025	-$0.29est. -$0.22	-31.82%miss	$63.7M · FYSEC filing	No year-ago quarter
Sep 30, 2024Reported Nov 14, 2024	-$0.22est. -$0.21	-4.76%miss	$15.4MSEC filing	+2.3%from $15.1M

Earnings per share comes from Yahoo Finance where available, then Alpha Vantage or the company release. Revenue comes from company releases, SEC filings, Alpha Vantage or Yahoo Finance. A beat or miss needs an analyst estimate on the same basis as the reported figure, so quarters without one show none. Non-USD amounts carry their currency code.

Open: $7.36
52-wk high: $16.44
High: $7.54
52-wk low: $6.00
Low: $7.29
Prev close: $7.29
Mkt cap: $1.60B
ROE: -73.0%
Beta: 0.99
P/S: 30.8x
P/B: 2.8x
Profit margin: +0.0%
Op margin: -609.0%

Fundamentals

Is the business strong?

This company is running thin margins.

Net margin: 0.0%
Market cap: $1.6B

Valuation

P/S30.76
P/B2.83

Quality

Operating margin-609.0%
ROE-73.0%
ROA-34.9%

Growth

Beta0.99

Technicals

Price structure

This stock's price action is mixed.

Trend

Mixed

55 / 100

RSI 14

47balanced

20D volatility

67%annualized

52-week range

$7.31

$6.00$16.44

20D support

$6.00recent floor

20D resistance

$7.75recent ceiling

Returns

5D +10.6%20D +0.3%60D -14.0%

Price vs moving averages

SMA20 +4.1%SMA50 -17.8%SMA200 -20.0%

Volume pace

0.95xvs prior 20D

Smart money at a glance

Filings to Oct 30, 2026

Net selling: insiders sold $568K and bought $0 on the open market in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.

Company insidersSEC Form 4, last 90 days: -$568K netNet selling
CongressSTOCK Act, last 180 days: NoneNo trades disclosed
Big fundsSEC 13F, quarter ended Mar 31, 2026: 1 added, 2 cutMore cutting
Federal contractsUSAspending.gov, last 12 months: No awardsNone on record

Analysts

What do analysts expect?

Analyst target and ratings are on paid plans

See the 12-month consensus target and the buy/hold/sell rating split.

Unlock the full results

Questions about OCUL filings

Are insiders buying or selling Ocular Therapeutix Inc (OCUL) stock?

Which members of Congress have traded OCUL recently?

None. No member of Congress disclosed a OCUL trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.

How current is this OCUL smart-money data?

13F: filed up to 45 days late.

Smart money on OCUL

Lean short2 sources:
- Insiders
- Funds

Top traders
No tracked positions at the last update
Insiders
Lean short3 sales · $234K
3 of 3 on scheduled plans. Form 4 filings.
Politicians
No recent politician filings found
Funds
Lean short1 added · 2 trimmed
Quarter-end 13F holdings changes, not live trades. A trim is not a short.
Fin-fluencers
No recent posts found

Each bar is 100% of that source’s money. The notch marks an even split.

Lean is the direction of the latest moves. Descriptive, not advice.

Questions about OCUL filings

Are insiders buying or selling Ocular Therapeutix Inc (OCUL) stock?

Which members of Congress have traded OCUL recently?

None. No member of Congress disclosed a OCUL trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.

How current is this OCUL smart-money data?

Funds

What funds are doing

3 moves · 6 mo

Buys/Adds$34.5MSells/Trims$63.3M

Buys/Adds (1)

P7
Point72
Steven Cohen · Q1 2026 13F
$34.5M
added
Signals like this: n=13770, 53% finished lower at D15, median -0.4% vs SPY -0.4%

Sells/Trims (2)

MI
Millennium
Israel Englander · Q1 2026 13F
$38.7M
trimmed
Signals like this: n=7469, 53% finished lower at D15, median -0.5% vs SPY -0.4%
CI
Citadel
Ken Griffin · Q1 2026 13F
$24.7M
trimmed

Unlock everything for $29/month

Unlock for $29/month

Reported Aug 3, 2026

Earnings came in 9.4% above what analysts expected.

Documents

Quarterly report10-Q Annual report10-K Every filing

Last report

Aug 3, 2026

Period ending

Jun 30, 2026

Earnings per share

-$0.35+9.44% beat

-$0.39 expected

Revenue

$13.5M

SEC filing

EPS: Yahoo Finance

Next report

Estimated report: Nov 3, 2026, in 4 days

Previous reports

Quarter / reported	Earnings per share	Beat or miss	Revenue / income	Revenue vs last year
Jun 30, 2026Reported Aug 3, 2026	-$0.35est. -$0.39	+9.44%beat	$13.5MSEC filing	+0.1%from $13.5M
Mar 31, 2026Reported May 5, 2026	-$0.40est. -$0.32	-27.59%miss	$10.8MSEC filing	+0.8%from $10.7M
Dec 31, 2025Reported Feb 5, 2026	-$0.29est. -$0.34	+13.86%beat	$13.3MYahoo Finance	No year-ago quarter
Sep 30, 2025Reported Nov 4, 2025	-$0.38est. -$0.35	-9.61%miss	$14.5MSEC filing	-5.7%from $15.4M
Jun 30, 2025Reported Aug 5, 2025	-$0.39est. -$0.35	-11.43%miss	$13.5MSEC filing	-18.1%from $16.4M
Mar 31, 2025Reported May 5, 2025	-$0.37est. -$0.28	-32.14%miss	$10.7MSEC filing	-27.6%from $14.8M
Dec 31, 2024Reported Mar 3, 2025	-$0.29est. -$0.22	-31.82%miss	$63.7M · FYSEC filing	No year-ago quarter
Sep 30, 2024Reported Nov 14, 2024	-$0.22est. -$0.21	-4.76%miss	$15.4MSEC filing	+2.3%from $15.1M

Open: $7.36
52-wk high: $16.44
High: $7.54
52-wk low: $6.00
Low: $7.29
Prev close: $7.29
Mkt cap: $1.60B
ROE: -73.0%
Beta: 0.99
P/S: 30.8x
P/B: 2.8x
Profit margin: +0.0%
Op margin: -609.0%

Fundamentals

Is the business strong?

This company is running thin margins.

Net margin: 0.0%
Market cap: $1.6B

Valuation

P/S30.76
P/B2.83

Quality

Operating margin-609.0%
ROE-73.0%
ROA-34.9%

Growth

Beta0.99

Technicals

Price structure

This stock's price action is mixed.

Trend

Mixed

55 / 100

RSI 14

47balanced

20D volatility

67%annualized

52-week range

$7.31

$6.00$16.44

20D support

$6.00recent floor

20D resistance

$7.75recent ceiling

Returns

5D +10.6%20D +0.3%60D -14.0%

Price vs moving averages

SMA20 +4.1%SMA50 -17.8%SMA200 -20.0%

Volume pace

0.95xvs prior 20D

Ocular Therapeutix Inc

Smart money at a glance

What do analysts expect?

Questions about OCUL filings

Smart money on OCUL

Questions about OCUL filings

What funds are doing

What insiders are doing

How top traders are positioned

Unlock everything for $29/month

Earnings came in 9.4% above what analysts expected.

Estimated report: Nov 3, 2026, in 4 days

Previous reports

Is the business strong?

Price structure

Ask it in Claude or ChatGPT.

Ocular Therapeutix Inc

Smart money at a glance

What do analysts expect?

Questions about OCUL filings

Smart money on OCUL

Questions about OCUL filings

What funds are doing

What insiders are doing

How top traders are positioned

Unlock everything for $29/month

Earnings came in 9.4% above what analysts expected.

Estimated report: Nov 3, 2026, in 4 days

Previous reports

Is the business strong?

Price structure

Ask it in Claude or ChatGPT.

Ocular Therapeutix Inc

Overview

Questions about OCUL filings

Smart money

Unlock everything for $29/month

Earnings

Previous reports

Financials

Technicals

Ask it in Claude or ChatGPT.

Ocular Therapeutix Inc

Overview

Questions about OCUL filings

Smart money

Unlock everything for $29/month

Earnings

Previous reports

Financials

Technicals

Ask it in Claude or ChatGPT.